Epstein–Barr virus infection in children with renal transplantation: 17 years experience at a single center

References

• Green M, Michaels MG. Epstein–Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13(Suppl 3):41–54
   PubMedGoogle Scholar
• Ponticelli C. Herpes viruses and tumours in kidney transplant recipients. The role of immunosuppression. Nephrol Dial Transplant. 2011;26:1769–1775
   PubMed Web of Science ®Google Scholar
• Gulley ML, Tang W. Using Epstein–Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev. 2010;23:350–366
   PubMed Web of Science ®Google Scholar
• Morgans AK, Reshef R, Tsai DE. Posttransplant lymphoproliferative disorder following kidney transplant. Am J Kidney Dis. 2010;55:168–180
   PubMed Web of Science ®Google Scholar
• Holemes RD, Sokol RJ. Epstein–Barr virus and posttransplant lymphoproliferative disease. Pediatr Nephrol. 2002;16:456–464
   Google Scholar
• Srivastava T, Zwick DL, Rothberg PG, Warady BA. Posttransplant lymphoproliferative disease in pediatric renal transplantation. Pediatr Nephrol. 1999;13:748–754
   PubMedGoogle Scholar
• Allen U, Herbert D, Moore D, et al. Epstein–Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988–97: a Canadian multicentre experience. Pediatr Transplant. 2001;5:198–203
   PubMed Web of Science ®Google Scholar
• Hoshino Y, Kimura K, Kuzushima K, et al. Early intervention in post-transplant lymphoproliferative disorders based on Epstein–Barr viral load. Bone Marrow Transpl. 2000;26:199–201
   PubMed Web of Science ®Google Scholar
• Lucas KG, Burton RL, Zimmerman SE, et al. Semiquantitative Epstein–Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood. 1998;91:3654–3661
   PubMed Web of Science ®Google Scholar
• Green M, Cacciarelli TV, Mazariegos GV, et al. Serial measurement of Epstein–Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation. 1998;66:1641–1644
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–S155
   PubMed Web of Science ®Google Scholar
• Frey NV, Tsai DE. The management of posttransplant lymphoproliferative disorder. Med Oncol. 2007;24:125–136
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol. 2009;24:731–736
   PubMed Web of Science ®Google Scholar
• Schwartz GJ, Munõz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–637
   PubMed Web of Science ®Google Scholar
• Koyun M, Hazar V, Akkaya B, et al. A case report: hepatic posttransplant lymphoproliferative disorder in a non-liver transplant patient. Transplant Proc. 2011;43:2102–2106
   PubMedGoogle Scholar
• Ellis D, Jaffe R, Green M, et al. Epstein–Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppresion. Transplantation. 1999;68:997–1003
   PubMed Web of Science ®Google Scholar
• Shroff R, Trompeter R, Cubitt D, Thaker U, Rees L. Epstein–Barr virus monitoring in paediatric renal transplant recipients. Pediatr Nephrol. 2002;17:770–775
   PubMed Web of Science ®Google Scholar
• Walker RC, Marshall WF, Strickler JC, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995;20:1346–1353
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ikezumi Y, Okubo S, et al. Epstein–Barr virus DNA load and seroconversion in pediatric renal transplantation with tacrolimus immunosuppression. Pediatr Transplant. 2007;11:749–754
   PubMedGoogle Scholar
• Ozkan A, Kilic SS, Kalkan A, et al. Seropositivity of Epstein–Barr virus in Eastern Anatolian Region of Turkey. Asian Pac J Allergy Immunol. 2003;21:49–53
   PubMedGoogle Scholar
• Opelz G, Daniel V, Naujokat C, Döhler B. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation. 2009;88:962–967
   PubMedGoogle Scholar
• Cleper R, Ben Shalom E, Landau D, et al. Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients – a national study. Pediatr Transplant. 2012;16:619–626
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Araya CE. Complications of renal transplantation. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, eds. Pediatric Nephrology. 6th ed. Berlin Heidelberg: Springer-Verlag; 2009:1919–1939
   Google Scholar
• Tsai DE, Douglas L, Andreadis C, et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant. 2008;8:1016–1024
   PubMed Web of Science ®Google Scholar
• Tsai DE, Nearey M, Hardy CL, et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant. 2002;2:946–954
   PubMed Web of Science ®Google Scholar
• Toyoda M, Moudgil A, Warady BA, Puliyanda DP, Jordan SC. Clinical significance of peripheral blood Epstein–Barr viral load monitoring using polymerase chain reaction in renal transplant recipients. Pediatr Transplant. 2008;12:778–784
   PubMedGoogle Scholar
• Ishihara M, Tanaka E, Sato T, et al. Epstein–Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients. Clin Nephrol. 2011;76:40–48
   PubMed Web of Science ®Google Scholar
• Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005;5:2222–2228
   PubMed Web of Science ®Google Scholar
• Smets F, Latinne D, Bazin H, et al. Ratio between Epstein–Barr viral load and anti-Epstein–Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation. 2002;73:1603–1610
   PubMed Web of Science ®Google Scholar
• Sato T, Fujieda M, Maeda A, et al. Monitoring of Epstein–Barr virus load and killer T cells in pediatric renal transplant recipients. Clin Nephrol. 2008;70:393–403
   PubMed Web of Science ®Google Scholar
• Guppy AE, Rawlings E, Madrigal JA, Amlot PL, Barber LD. A quantitative assay for Epstein–Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease. Transplantation. 2007;84:1534–1539
   PubMed Web of Science ®Google Scholar
• Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol. 2009;27:3354–3362
   PubMed Web of Science ®Google Scholar
• Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80:1233–1243
   PubMed Web of Science ®Google Scholar